Valneva signs $42 million Ixiaro supply contract with US government

16 March 2016

French biotech firm Valneva (Euronext: VLA), a leading pure play vaccine company, revealed today the signing of a $42 million contract with the US government's Department of Defense for the supply of its Japanese encephalitis (JE) vaccine Ixiaro.

Under the terms of the agreement, Valneva will supply Ixiarodoses to the Defense Logistics Agency (DLA), supply center of the US Department of Defense for a total value of $42 million over a two-year period (a base year and an option year). First deliveries are expected to commence in the coming weeks. Valneva’s shares rose 6.1% to3.48 euros following the news.

JE is a very serious and growing public health threat in Asia. The US Department of Defense has been using Ixiaro to protect the near 360,000 US military and civilian personnel, and their families, working and living in endemic countries since 2010.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK